Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

04/25/2013 | 08:25am US/Eastern
   By Ben Fox Rubin 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at

Order free Annual Report for Celgene Corp.

Visit or call +44 (0)208 391 6028

Recommend :
React to this article
1d ago CELGENE : Appoints Tuomo Patsi as President of EMEA and Commits to Continue Deli..
1d ago CELGENE : Zeldes Haeggquist & Eck, LLP : Announces Investigation of Celgene, Inc..
09/15 CELGENE : Assigned Patent
09/11 S&P 500 rebounds with energy shares; Dow dips
09/10 CELGENE : Phase III FIRST MM-020/IFM 07-01 trial of REVLIMID lenalidomide plus d..
09/10 CELGENE : Releases Data from Phase III First Trial of Revlimid
09/08 CELGENE : Assigned Patent
09/04 CELGENE : Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalido..
09/03 CELGENE : VentiRx Pharmaceuticals Provides Corporate and Clinical Update
09/02 CELGENE : VentiRx Pharmaceuticals Provides Corporate and Clinical Update
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
Celgene Corporation : Income Statement Evolution
More Financials
Dynamic quotes